Search clinical trials for: Cyclophosphamide,Fludarabine

Total 4217 results

City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
St. Petersburg State Pavlov Medical University

Terminated

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Myelodysplastic Syndromes | Leukemia, Chronic Myeloid | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Russian Federation
Masonic Cancer Center, University of Minnesota

Recruiting

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Myelodysplastic Syndromes | Fanconi Anemia | Dyskeratosis Congenita | Severe Aplastic Anemia | Bone Marrow Failure | T Cell Receptor Alpha/Beta Depletion | Telomere Biology Disorder

United States
NCIC Clinical Trials Group

Completed

Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

Canada, France
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL

Lymphoma, Large B-Cell, Diffuse | High-grade B-cell Lymphoma | Follicular Lymphoma Grade 3B | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
University Health Network, Toronto

Not yet recruiting

Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah (LOKI)

Lymphoma, Large B-Cell, Diffuse
University Health Network, Toronto
Takara Bio Inc.

Recruiting

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell Lymphoma

Canada
M.D. Anderson Cancer Center

Recruiting

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Adenocarcinoma | Pancreatic Cancer | Ovarian Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Precigen, Inc

Recruiting

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Triple Negative Breast Cancer Malignancies

United States
GlaxoSmithKline

Terminated

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Neoplasms

Germany, United States, Netherlands, Canada, Australia, Sweden
GlaxoSmithKline

Completed

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Neoplasms

United States
Henan Cancer Hospital
The Beijing Pregene Science and Technology Company, Ltd.

Unknown

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

B Cell Lymphoma

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
PNP Therapeutics, Inc.

Completed

Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors

Head and Neck Cancer

United States
M.D. Anderson Cancer Center
Vion Pharmaceuticals

Completed

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

Hematologic Malignancies

United States
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Kite, A Gilead Company

Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Relapsed and/or Refractory B-cell Lymphoma

United States, Netherlands, United Kingdom, Germany
University of Pennsylvania

Active, not recruiting

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

Prostate Cancer

United States
Stanford University

Active, not recruiting

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Lymphoma | B Cell Lymphoma | Acute Lymphoblastic Leukemia, Pediatric

United States
Allogene Therapeutics

Active, not recruiting

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA)

Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Large B Cell Lymphoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Skin Cancer | Metastatic Melanoma

United States
Czech CLL Study Group

Unknown

Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project (Q-lite)

Chronic Lymphocytic Leukemia

Czech Republic
M.D. Anderson Cancer Center

Completed

Non-Myeloablative Allogeneic Stem Cell Transplantation

Lymphoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease

Graft Versus Host Disease
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Progressive Disease | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Minimal Residual Disease | Recurrent Chronic Lymphocytic Leukemia | CD19 Positive | CD22...

United States
French Innovative Leukemia Organisation
Novartis; Schering SA

Completed

GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly

Acute Myeloid Leukemia

France
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Metastatic Castration-resistant Prostate Cancer

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Bristol-Myers Squibb Services Unlimited Company

Recruiting

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathy

United States, Belgium, France, Spain, Germany, Italy
Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE)

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

United States
Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (ALPHA2)

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

United States, Spain, Canada, Australia, Italy
National University of Malaysia
Gaia Science

Recruiting

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Relapsed B Acute Lymphoblastic Leukaemia | Refractory B Acute Lymphoblastic Leukaemia

Malaysia
University Hospital Heidelberg

Recruiting

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, Adult

Germany
Allogene Therapeutics

Active, not recruiting

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPAND)

Relapsed/Refractory Large B Cell Lymphoma

United States, Belgium
National Cancer Institute (NCI)

Completed

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Adult T-Cell Leukemia (ATL)

United States
The Second Affiliated Hospital of Henan University...
Xuzhou Medical University; Xinqiao Hospital of Chongqing

Unknown

Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma (MatchCART)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Miltenyi Biotec, Inc.

Completed

Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine

Fanconi Anemia

United States
Dutch Childhood Oncology Group
St. Jude Children's Research Hospital; International BFM Study Group

Completed

Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Neoplasms | Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Lymphoma, Mantle-Cell
Crystal Mackall, MD
National Institutes of Health (NIH); California Institute for Regenerative... and other collaborators

Recruiting

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

Glioma of Spinal Cord | Glioma of Brainstem

United States
Xijing Hospital
Xi'An Yufan Biotechnology Co.,Ltd

Recruiting

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Lymphoma, B-Cell | CD19 Positive | Leukemia Lymphocytic Acute (ALL) in Relapse | Leukemia Lymphocytic Acute (All) Refractory

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

T-cell Acute Lymphoblastic Lymphoma | T-non-Hodgkin Lymphoma

United States
TCR2 Therapeutics

Completed

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Follicular Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

United States
First Affiliated Hospital of Wenzhou Medical University
Second Affiliated Hospital of Nanchang University; Hrain Biotechnology Co.,...

Unknown

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia

China
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

Study of BCMA CAR-T in Multiple Myeloma

Multiple Myeloma

China
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

B-cell Acute Lymphocytic Leukemia

China
Genzyme, a Sanofi Company

Completed

Fludara (Oral) Phase II Study for Indolent Lymphoma

Lymphoma

Japan
Alice Bertaina
California Institute for Regenerative Medicine (CIRM)

Recruiting

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

CKD Stage 4 | Cystinosis | FSGS | SLE Nephritis | SIOD

United States
Kyverna Therapeutics

Not yet recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Systemic Sclerosis | Systemic Sclerosis - Diffuse Cutaneous | Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
The First People's Hospital of Lianyungang

Not yet recruiting

B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors

Advanced Solid Tumor

China

Search clinical trials for: Cyclophosphamide,Fludarabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations